Intermediate-term impact on corneal endothelial cells and efficacy of Preserflo MicroShunt implantation in patients with open-angle glaucoma – a prospective study over two years
Graefe's Archive for Clinical and Experimental Ophthalmology · 2024-11 · 262 (11) · 3661-3670
DOI: 10.1007/s00417-024-06508-8 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, online erschienen am 21.05.2024. Verfasst von Caroline J Gassel und 4 weiteren Autor:innen. Beteiligte Einrichtung: University Eye Hospital Tuebingen, Centre for Ophthalmology, Elfriede-Aulhorn-Str. 7, Tübingen, 72076, Germany. caroline.gassel@med.uni-tuebingen.de. Hauptthemen laut MEDLINE: Glaucoma, Open-Angle, Intraocular Pressure, Visual Acuity, Endothelium, Corneal. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinischen Fakultät, Eberhard Karls Universität Tübingen, Universitätsklinikum Tübingen.
Abstract (Originalsprache)
Introduction
Preserflo MicroShunt is a novel microinvasive bleb forming device for the treatment of primary open-angle glaucoma. The intermediate- and long-term success and the impact of this procedure on corneal endothelial cell density remain to be investigated.
Methods
In this prospective observational study, 62 eyes of 55 glaucoma patients (mean age ± SD: 67.0 ± 15.0 years) receiving a Preserflo MicroShunt were included. Corneal endothelial cell density, intraocular pressure and best corrected visual acuity were assessed preoperatively and at 3, 6, 9, 12, 18 and 24 months postoperatively. Success rates, bleb revision rates and complications were analysed. Complete success was defined as an intraocular pressure reduction of ≥ 20% and achieving a target pressure of ≤ 18, ≤ 15 or ≤ 12 mmHg without antiglaucoma medication. Qualified success indicated that the criteria were reached with or without medication.
Results
Corneal endothelial cells showed no significant decline over 24 months ( p > 0.05). Intraocular pressure showed a substantial reduction postoperatively ( p < 0.001), decreasing from 29.6 ± 8,3 mmHg to 13.0 ± 4.3 mmHg after 24 months ( p < 0.001). Complete and qualified success with a target pressure ≤ 15 mmHg was achieved in 52.9% and 54.6% of cases after 24 months, respectively. Best corrected visual acuity did not change after 24 months.
Conclusion
Preserflo MicroShunt had no negative side effects on corneal endothelial cells and showed favourable success rates after 2 years in patients with open-angle glaucoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Eye Hospital Tuebingen, Centre for Ophthalmology, Elfriede-Aulhorn-Str. 7, Tübingen, 72076, Germany. caroline.gassel@med.uni-tuebingen.de.
- University Eye Hospital Tuebingen, Centre for Ophthalmology, Elfriede-Aulhorn-Str. 7, Tübingen, 72076, Germany.
- Institute for Ophthalmic Research, Centre for Ophthalmology, Tuebingen, Germany.
Förderung
- Medizinischen Fakultät, Eberhard Karls Universität Tübingen
- Universitätsklinikum Tübingen
Zitieren
APA
Gassel, C. J., Wenzel, D. A., Nasyrov, E., Strasser, T., & Voykov, B. (2024). Intermediate-term impact on corneal endothelial cells and efficacy of Preserflo MicroShunt implantation in patients with open-angle glaucoma – a prospective study over two years. Graefe's Archive for Clinical and Experimental Ophthalmology, 262(11), 3661-3670. https://doi.org/10.1007/s00417-024-06508-8
Vancouver
Gassel CJ, Wenzel DA, Nasyrov E, Strasser T, Voykov B. Intermediate-term impact on corneal endothelial cells and efficacy of Preserflo MicroShunt implantation in patients with open-angle glaucoma – a prospective study over two years. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024;262(11):3661-3670. doi:10.1007/s00417-024-06508-8
BibTeX
@article{Gassel2024,
author = {Gassel, Caroline J and Wenzel, Daniel A and Nasyrov, Emil and Strasser, Torsten and Voykov, Bogomil},
title = {Intermediate-term impact on corneal endothelial cells and efficacy of Preserflo MicroShunt implantation in patients with open-angle glaucoma – a prospective study over two years},
journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
year = {2024},
volume = {262},
number = {11},
pages = {3661--3670},
doi = {10.1007/s00417-024-06508-8}
}
EUVIMED